Skip to main content

Peer Review reports

From: Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis

Original Submission
14 Aug 2022 Submitted Original manuscript
25 Aug 2022 Reviewed Reviewer Report - Takao Takeshima
29 Aug 2022 Reviewed Reviewer Report
11 Sep 2022 Author responded Author comments - Giorgio Lambru
Resubmission - Version 2
11 Sep 2022 Submitted Manuscript version 2
Publishing
12 Sep 2022 Editorially accepted
4 Nov 2022 Article published 10.1186/s10194-022-01507-8

You can find further information about peer review here.

Back to article page